Oaktree Acquisition Corp. III Life Sciences Unit carries a market capitalization of 262.37M, placing it among publicly traded companies globally.
| Market Cap | 262.37M |
| Enterprise Value | N/A |
Oaktree Acquisition Corp. III Life Sciences Unit currently has 24.58M shares outstanding.
| Shares Outstanding | 24.58M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 1.37 |
| P/TBV Ratio | 1.37 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Oaktree Acquisition Corp. III Life Sciences Unit maintains a current ratio of 0.73, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.73 |
| Quick Ratio | 0.68 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
| Return on Equity (ROE) | 3.47 |
| Return on Assets (ROA) | 3.33 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Oaktree Acquisition Corp. III Life Sciences Unit's stock has gained approximately 2.62911% over the past 52 weeks. The 50-day moving average sits at 10.81, while the 200-day moving average is 10.75.
| Beta (5Y) | N/A |
| 52-Week Price Change | 2.62911% |
| 50-Day Moving Average | 10.81 |
| 200-Day Moving Average | 10.75 |
| Average Volume (20 Days) | N/A |
EBITDA reached -1.20M, while operating income came in at -1.20M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -1.20M |
| Pretax Income | 6.75M |
| Net Income | 6.75M |
| EBITDA | -1.20M |
| EBIT | -1.20M |
| Earnings Per Share (EPS) | N/A |
Total book value stands at 197.79M, with working capital of -469,905.00 providing operational flexibility.
| Cash & Cash Equivalents | 1.18M |
| Total Debt | N/A |
| Net Debt | -1.17M |
| Equity (Book Value) | 197.79M |
| Book Value Per Share | 8.05 |
| Working Capital | -469,905.00 |
Oaktree Acquisition Corp. III Life Sciences Unit produced -455,689.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -455,689.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -455,689.00 |
| FCF Per Share | N/A |
Oaktree Acquisition Corp. III Life Sciences Unit posts an Altman Z-Score of 18.47, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 18.47 |